Results 181 to 190 of about 105,114 (279)

Ischaemic stroke and 5‐fluorouracil or capecitabine: A systematic review and meta‐analysis of harms and a retrospective study of the WHO pharmacovigilance database

British Journal of Pharmacology, EarlyView.
Abstract Aim Fluoropyrimidines, including 5‐fluorouracil (5‐FU) and capecitabine, are cornerstone antineoplastic agents for cancer. Case reports suggest that these drugs may be associated with an under‐recognised risk of ischaemic stroke or transient ischaemic attack (TIA).
Sophie Nguyen, Ines Bentahrour, Camille Guerin, Charles Dolladille, Angélique Da Silva, François Cherifi, Elise‐Marie Minoc, Pierre‐Marie Morice, Nicolas Jacquin, Christophe Le Tourneau, Joachim Alexandre, Ahmad Nehme, Etienne Bastien   +12 more
wiley   +1 more source

Aerobic Exercise Activates S1PR1 Signaling in Tumor Endothelial Cells to Promote Vascular Function in Pancreatic Cancer. [PDF]

Cancer Res
Ballarò R, Lam T, Pareek S, Lee J, Patel H, Tirumala P, Liu G, Hayek K, Savage H, De Maleki R, Guerrouahen BS, Ngo-Huang A, Parker NH, Katz MHG, Petzel MQ, McAllister F, Wright RD, Roy RA, Abraham RG, Pezeshki K, Tan L, Lorenzi PL, Schadler KL.   +22 more
europepmc   +1 more source

Targeting KRAS for cancer therapy

British Journal of Pharmacology, EarlyView.
In recent years, therapeutics targeted against KRAS proto‐oncogene GTPase (KRAS)‐mutant cancers have seen significant progress. Herein we outline the biology and epidemiology of KRAS alterations at the lineage and allele levels, reviewing the clinical evidence for KRASG12C inhibition from the discovery of the recessive switch pocket to sotorasib ...
Jianlong Jia, Ruonan Liu, Tonia A. Adamide, Isis E. Fernandez, Georgios T. Stathopoulos   +4 more
wiley   +1 more source

Comparative effectiveness of intravesical gemcitabine vs. sequential gemcitabine and docetaxel for high-risk nonmuscle-invasive bladder cancer. [PDF]

Urol Oncol
Moyer JA, Ashraf M, Mi L, Zganjar AJ, Lyon TD, Shah PH, Boorjian SA, Tyson MD.   +7 more
europepmc   +1 more source

Extracellular vesicles in pharmacology: Innovations in drug delivery and therapeutic applications in cancer

British Journal of Pharmacology, EarlyView.
Extracellular vesicles (EVs) are a diverse population of membrane nanoparticles secreted by nearly all cell types, playing a key role in intercellular communication by transferring bioactive macromolecular cargo. In cancer, EVs shape both the local tumour microenvironment and distant premetastatic niches.
Evangelia Pantazaka, Georgios Sivvas, Evangelia Papadimitriou, Constantinos M. Mikelis   +3 more
wiley   +1 more source

Metabolic and Molecular Mechanisms of Gemcitabine Resistance in Urothelial Carcinoma. [PDF]

Cancers (Basel)
Yamashita T, Nagamoto S, Arai M, Kitayama S, Yano A, Higashi M.   +5 more
europepmc   +1 more source

LAMC2+ Epithelial Cells Drive Bladder Cancer Progression and Predict Immunotherapy Response via SERPINB3/STAT3/CD44 Axis

Cancer Science, EarlyView.
This study identified LAMC2+ epithelial cells through single‐cell sequencing and found that high expression of LAMC2 is associated with the malignant progression of bladder cancer. HdWGCNA and transcriptome sequencing revealed the SerpinB3/STAT3/CD44 axis. Diosmetin was selected as a potential LAMC2 inhibitor.
Yutong Chen, Yunzhong Jiang, Zezhong Yang, Minxuan Jing, Wentai Wu, Jiale He, Lu Wang, Minghai Ma, Yaodong Zhang, Min Wang, Jianpeng Li, Yuanchun Pu, Bingliang He, Yanjia Liu, Kaibo Mi, Hang Liu, Mengzhao Zhang, Jinhai Fan   +17 more
wiley   +1 more source

RETRACTION: Comparison Efficacy and Safety of Gemcitabine plus Cisplatin and 5-Fluorouracil plus Cisplatin for Metastatic Nasopharyngeal Carcinoma: A Meta-Analysis and Systematic Review. [PDF]

J Oncol
Oncology JO.
europepmc   +1 more source

Daraxonrasib and Beyond: Pan‐RAS Inhibition, Resistance, and Next‐Generation Strategies

Cancer Science, EarlyView.
ABSTRACT RAS proteins have long been considered difficult therapeutic targets, but allele‐selective inhibitors established the clinical tractability of mutant RAS. Daraxonrasib (RMC‐6236), an oral pan‐RAS inhibitor, has now extended this concept by targeting multiple mutant and wild‐type RAS proteins.
Ryo Honda
wiley   +1 more source

Genotype‐Informed Whole‐Animal Kinome Screening Reveals Shared Kinase Vulnerabilities Across Driver Contexts in PDAC

Cancer Science, EarlyView.
Overview of experimental workflow and key findings. Clinically prevalent 2‐hit and 3‐hit PDAC genotypes were first modeled in Drosophila to enable kinome‐wide genetic screening. Candidate therapeutic targets were prioritized using human tumor expression data and pathway enrichment analyses.
Han Hai, Takako Ooshio, Hui Jiang, Taku Kimura, Yusuke Satoh, Soichiro Hata, Taiga Hirata, Jiayi Liu, Tongwei Liu, Ryodai Yamamura, Masahiro Sonoshita   +10 more
wiley   +1 more source